Pancreatic Cancer Market Size (2025-2030)

The Pancreatic Cancer Market was valued at USD 2.84 billion in 2024. Over the forecast period of 2025-2030 it is projected to reach USD 5.01 billion by 2030, growing at a CAGR of 12.01%.

When abnormal pancreatic cells grow and multiply without regulation, they can result in the development of a tumor referred to as pancreatic cancer. Key symptoms associated with this condition include persistent abdominal discomfort, unexplained weight loss, frequent diarrhea, yellowing of the skin and eyes (jaundice), and the occurrence of blood clots. Major risk factors contributing to the onset of pancreatic cancer comprise tobacco use, excessive body weight, a familial history of the disease, and older age.

Key Market Insights:

The expanding elderly population serves as a key driver for the pancreatic cancer market, as older individuals are more prone to requiring treatment due to a naturally declining immune response. Furthermore, increased awareness initiatives by both public and private entities regarding pancreatic cancer, its treatment options, and advancements in molecular biology have significantly contributed to the market’s recent growth. The rise in healthcare spending supports the enhancement of the industry’s infrastructure. Additionally, governmental bodies are actively investing in healthcare system improvements through increased funding initiatives.

Pancreatic Cancer Market Drivers:

Unhealthy lifestyle habits are considered a fundamental cause of pancreatic cancer, thereby contributing significantly to the growth of the pancreatic cancer market.

The likelihood of developing pancreatic cancer increases with excessive consumption of red and processed meats, meals high in saturated fats, alcoholic beverages, and foods and drinks containing fructose. Among these, alcohol consumption stands out as a major contributor to the onset of serious non-communicable diseases, including various forms of cancer, cardiovascular conditions, and liver cirrhosis. According to the World Health Organization, alcohol abuse is responsible for 3 million deaths globally, accounting for 5.3% of all fatalities. Additionally, approximately 13.5% of all deaths among individuals aged 20 to 39 are linked to alcohol use.

Smoking is responsible for roughly 25% of pancreatic cancer cases, with the risk of developing the disease being twice as high in smokers compared to non-smokers. Moreover, the use of cigars and smokeless tobacco products also contributes to the development of pancreatic cancer.

Progress in diagnostic technologies is a key factor driving the growth of the pancreatic cancer market.

Technological innovations in diagnostic methods are playing a pivotal role in advancing the pancreatic cancer market. The adoption of sophisticated imaging technologies such as Magnetic Resonance Imaging (MRI) and Endoscopic Ultrasound (EUS) has significantly enhanced the accuracy of pancreatic cancer detection, facilitating earlier diagnosis and timely treatment. According to the American Cancer Society, early diagnosis can notably increase survival rates, thereby contributing to better patient outcomes.

Additionally, the National Institutes of Health has supported multiple research and development initiatives focused on the identification of biomarkers, which are crucial in improving diagnostic precision. These advancements are expected to further stimulate demand for follow-up treatment options, thereby accelerating the growth of the pancreatic cancer market.

Rising investments in research and development activities serve as a major catalyst for the growth of the pancreatic cancer market.

The pancreatic cancer market is experiencing notable growth, driven by increased investments in research and development focused on discovering innovative therapies. Companies and research institutions are dedicating substantial resources to R&D initiatives aimed at advancing treatment modalities, including chemotherapy, targeted therapies, and immunotherapy. Funding from the National Cancer Institute has seen a significant rise, with annual investments surpassing $150 million for pancreatic cancer research.

This robust financial support is intended to stimulate groundbreaking advancements that could transform current treatment approaches. Strategic partnerships between biotechnology firms and governmental bodies play a crucial role in expediting these developments. The expected launch of novel therapeutic options is poised to address the growing demand for more effective treatment alternatives in the pancreatic cancer market.

Pancreatic Cancer Market Restraints and Challenges:

The elevated cost associated with pancreatic cancer treatment poses a significant barrier to market growth.

This elevated expense is largely driven by the introduction of new pharmaceutical drugs by leading industry players. As a result, patients often prioritize more affordable alternatives, such as herbal therapies. According to the American Society of Clinical Oncology, the average cost for a six-month chemotherapy regimen is approximately USD 23,500. When combined with the drug Erlotinib, treatment expenses can escalate to around USD 40,000.

The presence of severe side effects associated with pancreatic cancer treatments acts as a constraint on market growth.

Additional factors restraining the growth of the pancreatic cancer market include the severe side effects linked to chemotherapy drugs, such as pain, fever, vomiting, dizziness, and frequent bloody bowel movements. Moreover, radiation therapy is associated with side effects including urinary and bladder complications, diarrhea, altered taste sensation, and shortness of breath.

Pancreatic Cancer Market Opportunities:

The expansion of clinical research and development efforts broadens market reach, thereby driving growth in the pancreatic cancer market.

The pancreatic cancer market is characterized by significant opportunities driven by advancements in epidemiological, molecular, and fundamental clinical research, which contribute to improved prevention, diagnosis, and treatment methods. The pharmaceutical industry is witnessing strong growth fueled by increased clinical research and development activities.

As a result, the pancreatic cancer market is growing alongside advancements in the pharmaceutical industry, driven by continuous development efforts and increased investments in cancer therapeutics. This dynamic presents a promising opportunity for sustained market growth.

PANCREATIC CANCER MARKET REPORT COVERAGE:

Pancreatic Cancer Market Segmentation:

Pancreatic Cancer Market Segmentation By Type:

• Exocrine
• Endocrine

The exocrine segment maintains a dominant position in the pancreatic cancer market, primarily due to the increasing prevalence of exocrine pancreatic cancer within the patient population. Since the majority of the pancreas consists of exocrine cells, including exocrine ducts and glands, cancer typically originates in the pancreatic ducts, subsequently impacting the exocrine portion of the organ.

Moreover, the growing adoption of advanced diagnostic technologies has led to improved detection of pancreatic endocrine cancer. The elderly population is particularly vulnerable to endocrine pancreatic cancer, which is expected to contribute to the overall growth of the pancreatic cancer market.

The endocrine segment is anticipated to demonstrate significant growth during the forecast period. Endocrine pancreatic disorders arise from hormone-producing cells responsible for regulating essential functions such as blood glucose levels. Although less common, these conditions are frequently linked to risk factors including genetic predisposition, hormonal imbalances, and metabolic syndromes. Additionally, the increasing incidence of lifestyle-related diseases such as diabetes and obesity further drives the prevalence of endocrine pancreatic disorders.

Pancreatic Cancer Market Segmentation By Treatment Type:

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormone Therapy
• Others

The chemotherapy segment holds a substantial revenue share, maintaining a dominant position within the pancreatic cancer market. As a primary treatment option, a significant proportion of patients diagnosed with pancreatic cancer undergo chemotherapy. The growth of this segment is driven by chemotherapy’s ability to provide long-term protection by targeting and eliminating rapidly dividing abnormal cells.

Conversely, the radiation therapy segment is expected to experience notable growth during the forecast period. This expansion is attributed to the increasing adoption of advanced technologies in healthcare facilities, which facilitates the use of sophisticated radiation therapy equipment for the treatment of cancer patients.

Pancreatic Cancer Market Segmentation By End User:

• Clinics
• Hospitals
• Others

The hospital segment represents the highest revenue share in the pancreatic cancer market. This dominance is driven by the increasing number of patients receiving chemotherapy, radiation therapy, and other related treatments in hospital settings. As the primary choice for many patients, hospitals have incorporated emerging technologies for the diagnosis and treatment of pancreatic cancer, thereby contributing to the market’s expansion.

In addition, the clinics segment holds a significant market share, supported by a growing number of cancer patients seeking treatment at clinics. The expansion of this segment is further propelled by the increasing availability of clinics offering chemotherapy and radiation therapy, alongside the rising privatization facilitating the establishment of new clinics.

The retail pharmacy segment is also expected to witness considerable growth over the forecast period and is projected to be the fastest-growing segment. This growth is influenced by the rising number of retail pharmacies and patient demand. Retail pharmacies offer easy access to medications and drugs, making them a convenient option for patients. Moreover, the cost-effectiveness of retail pharmaceuticals has been a key factor driving the expansion of this segment.

Pancreatic Cancer Market Segmentation- by region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

North America dominates the global pancreatic cancer market, largely driven by its sophisticated healthcare infrastructure and the extensive use of advanced diagnostic technologies. Additionally, the increasing prevalence of pancreatic cancer in the United States, along with the presence of prominent industry players, significantly supports market growth in the region.

Within North America, the U.S. stands out as the dominant market. Factors such as the rising number of patients, the concentration of major pharmaceutical companies, and favorable government policies are expected to drive continued growth. The U.S. also exhibits the highest obesity rates globally, which contributes to an increased incidence of diabetes and, consequently, a higher risk of pancreatic malignancies.

The Asia Pacific region is expected to record the highest compound annual growth rate (CAGR) over the forecast period. This growth is driven by a rising prevalence of pancreatic cancer, enhancements in healthcare infrastructure, and a growing number of pharmaceutical companies focused on developing pancreatic cancer treatments.

In particular, the pancreatic cancer treatment market in China is expected to witness substantial growth, fueled by a rapidly aging population, increasing urbanization, and lifestyle changes that elevate disease incidence. Furthermore, government initiatives aimed at improving healthcare infrastructure and expanding insurance coverage are enhancing patient access to advanced therapies.

COVID-19 Pandemic: Impact Analysis

During the COVID-19 pandemic, the number of patient visits for cancer screening declined due to limited availability of healthcare personnel performing these procedures. Additionally, governments in multiple countries implemented new regulations aimed at minimizing the spread of the virus, which resulted in a reduction of surgical and diagnostic interventions.

Latest Trends/ Developments:

In August 2024, Exelixis, Inc. Was awarded Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its investigational therapy, cabozantinib, aimed at treating pancreatic neuroendocrine tumors (pNET). The company also received a Prescription Drug User Fee Act (PDUFA) target action date set for April 3, 2025, representing a significant milestone in its drug development pipeline.

In February 2024, Ipsen Biopharmaceuticals, Inc. secured FDA approval for its therapy irinotecan liposome (Onivyde), to be used in combination with oxaliplatin, fluorouracil, and leucovorin, as a first-line treatment for metastatic pancreatic adenocarcinoma. This approval marks a pivotal advancement in therapeutic options for this difficult-to-treat condition.

Key Players:

These are top 10 players in the Pancreatic Cancer Market :-

1. Novartis
2. AstraZeneca
3. Regeneron Pharmaceuticals
4. Johnson & Johnson
5. Teva Pharmaceutical Industries
6. Bristol-Myers Squibb
7. Eli Lilly
8. Amgen
9. Celgene
10. Sanofi